MyoKardia Inc. (NASDAQ:MYOK) shares reached a new 52-week high during trading on Friday . The company traded as high as $20.72 and last traded at $20.44, with a volume of 41,489 shares trading hands. The stock had previously closed at $19.66.

A number of research analysts recently commented on the company. Cowen and Company reaffirmed a “buy” rating on shares of MyoKardia in a research note on Friday, May 13th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price target on shares of MyoKardia in a research note on Thursday, May 12th. Zacks Investment Research raised MyoKardia from a “sell” rating to a “hold” rating in a research note on Thursday, April 28th. BMO Capital Markets assumed coverage on MyoKardia in a research note on Wednesday, July 20th. They issued an “outperform” rating and a $28.00 price target for the company. Finally, Credit Suisse Group AG reaffirmed a “buy” rating and issued a $20.00 price target (up previously from $16.00) on shares of MyoKardia in a research note on Tuesday, July 12th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. MyoKardia currently has an average rating of “Buy” and an average price target of $23.50.

The company has a 50-day moving average of $16.55 and a 200 day moving average of $12.20. The firm’s market capitalization is $538.48 million.

MyoKardia (NASDAQ:MYOK) last announced its earnings results on Tuesday, August 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.04. The firm earned $3.55 million during the quarter, compared to analysts’ expectations of $3.55 million. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. On average, analysts forecast that MyoKardia Inc. will post ($1.50) EPS for the current year.

MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.